



FOR IMMEDIATE RELEASE

**Media Contact – Mayo Clinic**

Duska Anastasijevic (507) 284-5005  
[anastasijevic.duska@mayo.edu](mailto:anastasijevic.duska@mayo.edu)

**Media Contact – Baxter**

Lauren Russ, (224) 948-5353  
[media@baxter.com](mailto:media@baxter.com)

**Investor Contact – Baxter**

Clare Trachtman, (224) 948-3085

**BAXTER AND MAYO CLINIC LAUNCH RESEARCH AND DEVELOPMENT  
COLLABORATION TO TRANSFORM PATIENT CARE**

- *Five-year agreement brings together clinical and development expertise of two long-time healthcare leaders*
- *First project will focus on unmet needs in kidney disease treatment*

**DEERFIELD, Ill. and JACKSONVILLE, Fla., MAY 31, 2017 – [Baxter International Inc.](#)**

(NYSE:BAX), a global medical products company, and [Mayo Clinic](#) today announced a new research and development collaboration to advance innovation across a spectrum of therapeutic areas where there are high unmet patient needs.

The collaboration agreement will bring together the clinical and development expertise at Baxter and Mayo Clinic, where clinicians and researchers will work side-by-side to advance new technologies and therapies that transform patient care. The primary emphasis of the collaboration will be in areas where breakthrough treatment options can be introduced and innovation can drive access to high-quality care. The first project will focus on kidney disease, with additional projects planned in other areas.

Approximately 14% of Americans have some degree of chronic kidney disease (CKD),

**BAXTER AND MAYO CLINIC LAUNCH RESEARCH AND DEVELOPMENT  
COLLABORATION TO TRANSFORM PATIENT CARE – Page 2**

and nearly half also have diabetes and/or cardiovascular disease – the two major causes of CKD.<sup>1</sup>

“We are excited about combining Mayo’s clinical and research expertise with Baxter’s ability to apply and scale innovation,” says [Gianrico Farrugia, M.D.](#), vice-president of Mayo Clinic and the CEO of Mayo Clinic in Florida where the collaboration will commence. “We are confident that this collaboration will help accelerate discoveries, development and application of life-changing therapies for patients.”

“Baxter is pleased to work with Mayo Clinic, a world-renowned healthcare organization that shares Baxter’s passion for advancing patient-focused innovation,” said [José \(Joe\) E. Almeida](#), chairman and chief executive officer, Baxter. “The combined power of our two organizations will help us advance new solutions to the most pressing healthcare challenges, further delivering on Baxter’s mission to save and sustain lives.”

The initial agreement is for a five-year period, with a five-year renewal option. Additional details of the agreement were not disclosed.

###

**About Baxter**

[Baxter](#) provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the

**BAXTER AND MAYO CLINIC LAUNCH RESEARCH AND DEVELOPMENT  
COLLABORATION TO TRANSFORM PATIENT CARE – Page 3**

company's rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

**About Mayo Clinic**

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit [mayoclinic.org/about-mayo-clinic](http://mayoclinic.org/about-mayo-clinic) or [newsnetwork.mayoclinic.org](http://newsnetwork.mayoclinic.org).

---

<sup>1</sup> National Institute of Diabetes and Digestive and Kidney Diseases. <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease>. Accessed May 30, 2017